SCHEMBL308042

SCHEMBL308042

O=Cc1ccc2nccn2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 1/20 0.55
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
CYP1A2 P05177 1/20 0.50
DYRK1A Q13627 2/20 0.49
KEAP1 Q14145 1/20 0.49
ALDH1A1 P00352 3/20 0.42
ESR1 P03372 1/20 0.40
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAOB P27338 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MAPK1 P28482 1/20 0.37
MCHR1 Q99705 1/20 0.37
TGFBR1 P36897 3/20 0.36
RET P07949 1/20 0.36
DAO P14920 1/20 0.35
PDE4A P27815 1/20 0.35
PDE3A Q14432 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8828283 0.86 DYRK1A (0.65) PIK3CGMEN1KMT2ACYP1A2DYRK1A
SCHEMBL25816400 0.82 PIK3CG (0.50) PIK3CGMEN1KMT2ACYP1A2DYRK1A
SCHEMBL16693216 0.77 PIK3CG (0.48) PIK3CGMEN1KMT2ACYP1A2DYRK1A
SCHEMBL31380880 0.77 MAP4K4 (0.54) PIK3CGMEN1KMT2ACYP1A2DYRK1A
SCHEMBL10568910 0.77 PIK3CG (0.48) PIK3CGMEN1KMT2ACYP1A2DYRK1A
SCHEMBL10572134 0.74 KEAP1 (0.64) PIK3CGMEN1KMT2ACYP1A2DYRK1A
SCHEMBL4441720 0.74 MEN1 (0.47) PIK3CGMEN1KMT2ACYP1A2DYRK1A
SCHEMBL27904946 0.74 PIK3CG (0.46) PIK3CGMEN1KMT2ACYP1A2DYRK1A
SCHEMBL22166413 0.73 NAMPT (0.65)
SCHEMBL12074123 0.73 DYRK1A (0.43) PIK3CGCYP1A2DYRK1ATGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113164459-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-03 CN claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
US-12492188-B2 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis BRISTOL-MYERS SQUIBB COMPANY (US) 2025-12-09 US disclosed
US-20250059207-A1 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS 858 THERAPEUTICS, INC. 2025-02-20 US disclosed
EP-4200292-B1 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS BRISTOL MYERS SQUIBB CO (US) 2024-11-13 EP disclosed
CN-113164459-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-03 CN disclosed
EP-3694846-B1 1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS HIV PROTEASE INHIBITORS GILEAD SCIENCES INC (US) 2024-05-08 EP disclosed
CN-117720533-A MetTL3 inhibitor compound and pharmaceutical composition and application thereof 北京华益健康药物研究中心 2024-03-19 CN disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
CN-112574175-B Quinoline compound, preparation method and application thereof 南京长澳医药科技有限公司 2023-11-14 CN disclosed
US-5606061-A HYPOTENSIVE AGENTS, ANTIASTHMATICS EISAI CO., LTD. (JP) 1997-02-25 US disclosed
US-5498634-A TREATING HYPERTENSION, ANGINA, ATP-SENSITIVE POTASSIUM CHANNEL AND ASTHMA EISAI CO., LTD. (JP) 1996-03-12 US disclosed
US-5444066-A Thioformamide derivatives having hypotensive activity EISAI CO., LTD. (JP) 1995-08-22 US disclosed
EP-0609442-A1 THIOFORMAMIDE DERIVATIVE Eisai Co., Ltd. (JP) 1994-08-10 EP disclosed
EP-0199127-B1 5-(6-imidazo[1,2-a]pyridyl) pyridine derivative Eisai Co., Ltd. (JP) 1989-12-13 EP disclosed
US-4803276-A CARDIOTONIC AGENTS, VASODILATION EISAI CO., LTD. (JP) 1989-02-07 US disclosed
US-4791202-A CARDIOTONIC AGENTS; CONGESTIVE HEART FAILURE EISAI CO., LTD. (JP) 1988-12-13 US disclosed
US-4791203-A CARDIOTONIC AGENTS EISAI CO., LTD. (JP) 1988-12-13 US disclosed
US-4751227-A 3-cyano-5-(6-imidazo[1,2-a]pyridyl)pyridin-2-ols useful as cardiotonics EISAI CO., LTD. (JP) 1988-06-14 US disclosed
EP-0199127-A1 5-(6-imidazo[1,2-a]pyridyl) pyridine derivative Eisai Co., Ltd. (JP) 1986-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059207-A1 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS METTL3, METTL16, TPMT PIK3CG 4409/4885MEN1 2065/4885KMT2A 319/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH PIK3CG 1916/4885MEN1 4537/4885KMT2A 3729/4885
US-12492188-B2 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis TLR9, TLR1, TLR7 PIK3CG 2024/4885MEN1 3868/4885KMT2A 898/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP PIK3CG 684/4885MEN1 4128/4885KMT2A 1069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.